ARC Therapy to Restore Hemodynamic Stability and Trunk Control in People With Spinal Cord Injury
HemON-NL
1 other identifier
interventional
16
1 country
1
Brief Summary
The goal of this interventional study is to evaluate the safety and preliminary effectiveness of the ARC-IM Therapy to improve hemodynamic management in people with sub-acute or chronic spinal cord injury. Participants will be implanted with the ARC-IM Thoracic System which aim to deliver, at the low thoracic level, targeted epidural electrical stimulation that will support natural hemodynamic control.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Sep 2023
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 4, 2023
CompletedFirst Posted
Study publicly available on registry
July 12, 2023
CompletedStudy Start
First participant enrolled
September 5, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
September 30, 2025
CompletedNovember 1, 2023
October 1, 2023
2.1 years
July 4, 2023
October 31, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Occurence of Serious Adverse Event and Adverse Events that are deemed related or possibly related to the study procedure or to the ARC-IM Thoracic System
Assess the safety of ARC-IM Therapy at supporting the management of hemodynamic instability with sub-acute or chronic spinal cord injury suffering from orthostatic hypotension
Throughout study, average of 15.5 months
Study Arms (1)
All participants
EXPERIMENTALAll participants will be provided with the ARC-IM Thoracic System (implantable and non-implantable parts)
Interventions
Implantation of the ARC-IM Thoracic Lead on the low thoracic level of the spinal cord and implantation of the ARC-IM IPG in the abdominal region
Eligibility Criteria
You may qualify if:
- years of age or older
- Must provide and sign the Informed Consent prior to any study-related procedures
- Traumatic Spinal Cord Injury
- Spinal cord injury lesion level between C3 and T6 (inclusive)
- AIS- A, B, C or D
- SCI ≥ 1month
- Confirmed orthostatic hypotension
- Stable medical, physical and psychological condition as considered by the investigators
- Able to understand and interact with the study team in Dutch or English
- Agrees to comply in good faith with all conditions of the study and to attend all scheduled appointments
- In case participants need continuous support from a personal caregiver in daily life, then the presence of their caregiver during the visits to the study site is needed, including independent transport (not dependent on a cab)
You may not qualify if:
- Diseases and conditions that would increase the morbidity and mortality of spinal cord injury surgery
- Diseases and conditions that would require regular MRI
- The inability to perform an MRI due to metal, magnetic or electrical device in the body (e.g. oral implant with magnet, mtal splinter, neurostimulator, artificial heart valve, clips, stents...) as assessed by the MRI form of Sint Maartenskliniek
- The inability to withhold antiplatelet/anticoagulation agents perioperatively
- History of myocardial infarction or cerebrovascular event within the past 6 months
- Other conditions that would make the subject unable to participate in testing in the judgement of the investigators
- Clinically significant mental illness in the judgement of the investigators
- Botulinum toxin non-vesical and vesical injections in the previous 3 months before the enrolment
- Presence of significant pressure ulcers
- Recurrent urinary tract infection refractory to antibiotics
- Presence of indwelling baclofen (e.g. intrathecal baclofen pump) or insulin pump
- Women who are pregnant (pregnancy test obligatory for woman of childbearing potential) or breast feeding
- Lack of safe contraception for women of childbearing capacity
- Intention to become pregnant during the course of the study,
- Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.)
- +3 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Sint Maartenskliniek
Ubbergen, 6574NA, Netherlands
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ilse Van Nes, MD, PhD
Sint Maartenskliniek, department of rehabilitation
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 4, 2023
First Posted
July 12, 2023
Study Start
September 5, 2023
Primary Completion
September 30, 2025
Study Completion
September 30, 2025
Last Updated
November 1, 2023
Record last verified: 2023-10